Robeco Institutional Asset Management B.V. Has $245.78 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Robeco Institutional Asset Management B.V. trimmed its Pfizer stake by 13.4%, selling 1,527,922 shares and now owning 9,870,643 shares worth about $245.78 million (≈0.17% of the company).
• Pfizer beat Q4 estimates with EPS of $0.66 versus $0.57 expected and revenue of $17.56 billion versus $16.93 billion, though the stock is trading down about 1.2% and the company has a market cap of $152.99 billion.
• Analyst sentiment is mixed: the consensus rating is "Hold" with an average target of $28.14, while recent moves range from an Argus upgrade to Buy (PT $35) to Bank of America cutting its target to $26 (Neutral).

Robeco Institutional Asset Management B.V. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,870,643 shares of the biopharmaceutical company's stock after selling 1,527,922 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.17% of Pfizer worth $245,779,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Fiduciary Alliance LLC grew its holdings in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company's stock worth $3,701,000 after acquiring an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Pfizer during the 3rd quarter worth approximately $3,019,000. Money Concepts Capital Corp grew its holdings in Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company's stock worth $6,325,000 after acquiring an additional 57,188 shares during the last quarter. Vista Investment Partners LLC grew its holdings in Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company's stock worth $1,774,000 after acquiring an additional 48,900 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA bought a new stake in Pfizer during the 3rd quarter worth approximately $16,613,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. TD Cowen reissued a "hold" rating on shares of Pfizer in a report on Tuesday, December 30th. Argus raised shares of Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price objective on the stock in a research note on Monday, March 2nd. Daiwa Securities Group lowered shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price objective on the stock. in a research note on Thursday, February 12th. Morgan Stanley upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research note on Friday. Finally, Bank of America reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $28.14.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Morgan Stanley raised its price target to $28 and kept an "equal weight" rating, implying modest upside and signaling some confidence in near-term fundamentals. Morgan Stanley raises PFE price target (Benzinga)
• Positive Sentiment: MarketWatch noted a recent intraday uptick (but continued underperformance versus the broader market), which can attract short-term buyers looking for mean-reversion after pullbacks. Pfizer Inc. stock rises Wednesday (MarketWatch)
• Neutral Sentiment: Zacks flagged Pfizer as a "trending" stock, meaning elevated retail/institutional attention — this can increase volatility but doesn’t by itself indicate direction. Pfizer is a trending stock (Zacks)
• Neutral Sentiment: Coverage pieces (Yahoo/MSN) are re-examining Q4 earnings, one-year performance and valuation after a strong one‑year gain; these narratives shape whether investors view PFE as fairly valued or still a buy. Is Pfizer Offering Value (Yahoo) Q4 earnings highs and lows (MSN)
• Neutral Sentiment: Pfizer announced its virtual Annual Meeting on April 23; routine corporate governance items can temper short-term trading but are unlikely to change fundamentals. Annual meeting webcast (BusinessWire)
• Neutral Sentiment: Industry research on the biopharmaceutical CXO market cites Pfizer among large players navigating outsourcing and supply-chain trends — a background macro theme that could help longer-term margins but is not an immediate catalyst. Biopharmaceutical CXO market report (Yahoo/GlobeNewswire)
• Negative Sentiment: Bank of America cut its price target to $26 and moved to "neutral," signaling downside risk and adding selling pressure from model-driven desks. Bank of America lowers PFE PT (Benzinga)
• Negative Sentiment: Zacks ran a comparative piece showing AbbVie (ABBV) pulling ahead on strong growth from Skyrizi and Rinvoq, underscoring competitive headwinds in immunology that could pressure Pfizer’s growth multiple. AbbVie vs Pfizer growth comparison (Zacks)
• Negative Sentiment: Coverage explaining why Pfizer tumbled earlier in the week highlights mixed near-term signals (analyst downgrades, rotation to other healthcare names), which can prolong weak sentiment even after small positive data points. Why Pfizer stock tumbled (Yahoo)

Pfizer Stock Down 1.2%

Shares of NYSE PFE opened at $26.91 on Friday. The firm has a market cap of $152.99 billion, a PE ratio of 19.78 and a beta of 0.43. Pfizer Inc. has a 12-month low of $21.28 and a 12-month high of $28.75. The company's fifty day simple moving average is $27.20 and its 200 day simple moving average is $25.94. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer's revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 earnings per share. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.